7n-Butylamino-6-methyl-1H-pyrazolo[4,3-b]pyridine | 105365-96-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡唑并吡啶类
• 英文名称: 7n-Butylamino-6-methyl-1H-pyrazolo[4,3-b]pyridine
• 英文别名: N-butyl-6-methyl-1H-pyrazolo[4,3-b]pyridin-7-amine
• CAS: 105365-96-6
• 化学式: C₁₁H₁₆N₄
• 分子量: 204.275
• InChiKey: MOGPVCIIOLBTGQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  53.6
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  ethyl 7-n-butylamino-1H-pyrazolo[4,3-b]-pyridine-6-carboxylate 在 sodium hydroxide 作用下， 以 四氢呋喃 、 水 为溶剂， 生成 7n-Butylamino-6-methyl-1H-pyrazolo[4,3-b]pyridine
  参考文献：
  名称：

  US4837238

  摘要：

  公开号：

文献信息

• Pharmacologically useful pyrazolopyridines
  申请人：Beecham Group p.l.c.

  公开号：US04837238A1

  公开（公告）日：1989-06-06

  Compounds of the formula (I): ##STR1## wherein: X is NR wherein R is hydrogen, C.sub.1-6 alkyl; oxygen; sulphur; SO; or SO.sub.2 ; or R and R.sub.3 taken together are C.sub.4-6 polymethylene; R.sub.1 is hydrogen or C.sub.1-6 alkyl; and R.sub.2 is CN, CR.sub.5 R.sub.6 Y where R.sub.5 and R.sub.6 are independently selected from hydrogen and C.sub.1-4 alkyl and Y is selected from hydrogen, OR.sub.7 or SR.sub.7 where R.sub.7 is hydrogen, C.sub.1-4 alkyl, C.sub.2-4 alkanoyl, and NR.sub.8 R.sub.9 where R.sub.8 and R.sub.9 are independently hydrogen, C.sub.1-4 alkyl, C.sub.2-4 alkenyl or C.sub.2-4 alkanoyl or R.sub.8 and R.sub.9 together are C.sub.4-6 polymethylene, or COR.sub.10 where R.sub.10 is C.sub.1-4 alkyl, provided that Y is other than hydrogen when R.sub.1 is hydrogen; or R.sub.2 is hydrogen C.sub.1-6 alkyl or phenyl optionally substituted by halogen, CF.sub.3, C.sub.1-4 alkoxy or C.sub.1-4 alkyl; and R.sub.1 is CN, CR.sub.5 R.sub.6 Y or COR.sub.10 as defined for R.sub.2 above; or R.sub.1 and R.sub.2 together form C.sub.3 -C.sub.6 polymethylene optionally substituted by C.sub.1 -C.sub.4 alkyl; R.sub.3 is C.sub.1-10 alkyl or C.sub.3-10 cycloalkyl, either optionally substituted by hydroxy, C.sub.1-4 alkoxy, thiol, C.sub.1-4 alkylthio or NR.sub.11 R.sub.12 wherein R.sub.11 and R.sub.12 are independently hydrogen, C.sub.1-6 alkyl or C.sub.2-7 alkanoyl or together are C.sub.3-6 polymethylene; C.sub.2-10 alkenyl; or phenyl optionally substituted by one or two of halogen, CF.sub.3, C.sub.1-4 alkoxy, C.sub.1-4 alkyl, hydroxy, nitro, cyano, C.sub.2-10 acyloxy, NR.sub.13 R.sub.14 wherein R.sub.13 and R.sub.14 are independently selected from hydrogen, C.sub.1-6 alkyl, C.sub.2-7 alkanoyl, C.sub.1-6 alkylsulphonyl or COR.sub.15 wherein R.sub.15 is hydroxy, C.sub.1-6 alkoxy or NR.sub.16 R.sub.17 wherein R.sub.16 and R.sub.17 are independently selected from hydrogen or C.sub.1-6 alkyl; or together with R is C.sub.4-6 polymethylene; and R.sub.4 is hydrogen; or C.sub.1-4 alkyl or benzyl optionally substituted in the phenyl ring by one or two of halogen, CF.sub.3, C.sub.1-4 alkoxy or C.sub.1-4 alkyl and is attached at nitrogen atom 1 or 2, are disclosed as having utility in the treatment of inflammatory and allergic disorders.

  式(I)的化合物：##STR1## 其中：X是NR，其中R是氢，C.sub.1-6烷基; 氧; 硫; SO; 或SO.sub.2; 或R和R.sub.3一起取C.sub.4-6聚亚甲基; R.sub.1是氢或C.sub.1-6烷基; R.sub.2是CN，CR.sub.5R.sub.6Y，其中R.sub.5和R.sub.6独立选择自氢和C.sub.1-4烷基，Y选择自氢，OR.sub.7或SR.sub.7，其中R.sub.7是氢，C.sub.1-4烷基，C.sub.2-4烷酰基和NR.sub.8R.sub.9，其中R.sub.8和R.sub.9独立选择自氢，C.sub.1-4烷基，C.sub.2-4烯基或C.sub.2-4烷酰基，或R.sub.8和R.sub.9一起取C.sub.4-6聚亚甲基，或COR.sub.10，其中R.sub.10是C.sub.1-4烷基，前提是当R.sub.1是氢时，Y不是氢；或R.sub.2是氢C.sub.1-6烷基或苯基，可选地被卤素，CF.sub.3，C.sub.1-4烷氧基或C.sub.1-4烷基取代；R.sub.1是CN，CR.sub.5R.sub.6Y或COR.sub.10，如上所定义的R.sub.2；或R.sub.1和R.sub.2一起形成C.sub.3-C.sub.6聚亚甲基，可选地被C.sub.1-C.sub.4烷基取代；R.sub.3是C.sub.1-10烷基或C.sub.3-10环烷基，可选地被羟基，C.sub.1-4烷氧基，硫醇，C.sub.1-4烷基硫醇或NR.sub.11R.sub.12取代，其中R.sub.11和R.sub.12独立选择自氢，C.sub.1-6烷基或C.sub.2-7酰基，或者一起是C.sub.3-6聚亚甲基；C.sub.2-10烯基；或苯基，可选地被卤素，CF.sub.3，C.sub.1-4烷氧基，C.sub.1-4烷基，羟基，硝基，氰基，C.sub.2-10酰氧基，NR.sub.13R.sub.14，其中R.sub.13和R.sub.14独立选择自氢，C.sub.1-6烷基，C.sub.2-7酰基，C.sub.1-6烷基磺酰基或COR.sub.15，其中R.sub.15是羟基，C.sub.1-6烷氧基或NR.sub.16R.sub.17，其中R.sub.16和R.sub.17独立选择自氢或C.sub.1-6烷基；或与R一起为C.sub.4-6聚亚甲基；R.sub.4是氢；或C.sub.1-4烷基或苯甲基，可选地在苯环上被一或两个卤素，CF.sub.3，C.sub.1-4烷氧基或C.sub.1-4烷基取代，并连接在氮原子1或2上，被用于治疗炎症和过敏性疾病。
• Pyrazolopyridines, their preparation and pharmaceutical compositions containing them
  申请人：BEECHAM GROUP PLC

  公开号：EP0193329A2

  公开（公告）日：1986-09-03

  Compounds of the formula (I): wherein: X is NR wherein R is hydrogen, C1-6 alkyl or as defined hereinafter with R3; oxygen; sulphur; SO; or SO2; R, is hydrogen or C1-6alkyl; and R2 is CN, CR5R6Y where Rs and R6 are independently selected from hydrogen and C1-4 alkyl and Y is selected from hydrogen, OR, or SR, where R7 is hydrogen, C1-4 alkyl or C2-4 alkanoyl, and NR8R9 where R8 and R9 are independently hydrogen, C1-4 alkyl, C 2.4 alkenyl or C2-4 alkanoyl or together are C 4-6 polymethylene, or COR10 where R,o is C1-4 alkyl, provided that Y is other than hydrogen when R, is hydrogen; or R2 is hydrogen, C1-6 alkyl or phenyl optionally substituted by halogen, CF3, C1-4 alkoxy or C1-4 alkyl; and R, is CN, CR5R6Y or COR10 as defined for R2 above; or R1 and R2 together form C3-C6 polymethylene optionally substituted by C1-C4 alkyl; R3 is C1-10 alkyl or C3-10 cycloalkyl, eitheroptionally substituted by hydroxy, C1-4 alkoxy, thiol, C1-4alkylthio or NR11R12 wherein R,, and R12 are independently hydrogen, C1-6 alkyl or C 2-7 alkanoyl or together are C3.6 polymethylene; C2-10 alkenyl; or phenyl optionally substituted by one or two of halogen, CF,, C1-4 alkoxy, C1-4 alkyl, hydroxy, nitro, cyano, C2-10 acyloxy, NR13R14 wherein R13 and R14 are independently selected from hydrogen, C1-6 alkyl, C2-7alkanoyl or C1-6 alkylsulphonyl or COR15 wherein R15 is hydroxy, C1-6 alkoxy or NR16R17 wherein R16 and R,7 are independently selected from hydrogen or C1-6 alkyl; or together with R is C 4-6 polymethylene; and R4 is hydrogen; or C1-4 alkyl or benzyl optionally substituted in the phenyl ring by one or two of halogen, CF3, C1-4 alkoxy or C1-4 alkyl and is attached at nitrogen atom 1 or 2, are disclosed as having utility in the treatment of inflammatory and allergic disorders.

  式 (I) 的化合物： 其中 X 是 NR，其中 R 是氢、C1-6 烷基或下文定义的 R3、氧、硫、SO 或 SO2； R，是氢或 C1-6 烷基；和 R2 是 CN、CR5R6Y（其中 Rs 和 R6 独立选自氢和 C1-4 烷基）和 Y（选自氢、OR 或 SR），其中 R7 是氢、C1-4 烷基或 C2-4 烷酰基，和 NR8R9（其中 R8 和 R9 独立是氢、C1-4 烷基、C 2.4 烯基或 C2-4 烷酰基）或一起是 C 4-6 聚亚甲基，或 COR10（其中 R，o 是 C1-4 烷基），条件是当 R，是氢时，Y 不是氢； 或 R2 是氢、C1-6 烷基或任选被卤素、CF3、C1-4 烷氧基或 C1-4 烷基取代的苯基；且 R 是 CN、CR5R6Y 或 COR10，如上文对 R2 所定义； 或 R1 和 R2 共同形成任选被 C1-C4 烷基取代的 C3-C6 聚亚甲基； R3是C1-10烷基或C3-10环烷基，任选被羟基、C1-4烷氧基、硫醇、C1-4烷硫基或NR11R12取代，其中R,,和R12独立地是氢、C1-6烷基或C 2-7烷酰基，或一起是C3.6聚亚甲基；C2-10烯基；或可选被卤素、CF、C1-4烷氧基、C1-4烷基、羟基、硝基、氰基、C2-10酰氧基、NR13R14（其中R13和R14独立地选自氢、C1-6烷基、C2-7烷酰基或C1-6烷基磺酰基）或COR15（其中R15是羟基、C1-6烷氧基或NR16R17（其中R16和R,7独立地选自氢或C1-6烷基）或与R一起是C 4-6聚亚甲基中的一个或两个取代的苯基）取代的苯基。 R4 是氢；或 C1-4 烷基或苄基，可选择在苯环上被卤素、 、C1-4 烷氧基或 C1-4 烷基中的一个或两个取代，并连接在氮原子 1 或 2 上。
• US4837238A
  申请人：——

  公开号：US4837238A

  公开（公告）日：1989-06-06